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S U M M A R Y
Background: The treatment of severe bloodstream infections (sepsis, endocarditis, and infections of
vascular prostheses) caused by Gram-positive microorganisms is made even more difﬁcult by the
emergence of resistant strains. The introduction of new antibiotics with activity against these strains has
created new opportunities, but many controversial issues remain.
Controversial issues: The aim of this GISIG (Gruppo Italiano di Studio sulle Infezioni Gravi) working
group – a panel of multidisciplinary experts – was to deﬁne recommendations for some controversial
issues using an evidence-based and analytical approach. The controversial issues concerned the
duration of therapy and role of aminoglycosides and teicoplanin in the treatment of Gram-positive
bacterial endocarditis, the optimal use of the new antibiotics in the treatment of bloodstream
infections caused by resistant Gram-positive strains, and the use of microbiological techniques (i.e.,
bactericidal serum testing and synergy testing) and of pharmacokinetic data (e.g., monitoring of
plasma levels of antibiotics) in the treatment of difﬁcult-to-treat Gram-positive bloodstream
infections.
Methods: A systematic literature search of randomized controlled trials and/or non-randomized studies
was performed mainly using the MEDLINE database. A matrix was created to extract evidence from
original studies using the CONSORT method to evaluate randomized clinical trials and the Newcastle–
Ottawa Quality Assessment Scale for non-randomized studies. The GRADE method for grading the
quality of evidence and strength of recommendation was applied.
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Bloodstream infections are among the most serious and severe
bacterial infections, with high mortality rates. The recent increase
in antibiotic resistance among Gram-positive bacteria has changed
the clinical scenario, making the treatment of these infections
more difﬁcult.
Infective endocarditis (IE), which is mainly caused by Gram-
positive bacteria, has become more difﬁcult to treat after the
emergence of antibiotic resistance in its main etiological agents
(streptococci, staphylococci and enterococci). Infection by methi-
cillin-resistant Staphylococcus aureus (MRSA) has spread in an
epidemic way, especially in some areas of the world, such as Spain,
wheremore than 25% of hospital-isolated strains are reported to be
resistant to methicillin.1 Moreover, the problem of methicillin
resistance in S. aureus is nowadays no longer restricted to hospital-
acquired infections following the emergence of community-
acquired MRSA in the USA.2 Also alarming is the development
of intermediate- and high-level resistance to vancomycin in strains
of S. aureus.3,4 Vancomycin resistance is common in many
nosocomial settings, and now also viridans streptococci, once a
leading cause of subacute IE, are increasingly acquiring resistance
to penicillin and other b-lactam antibiotics.5,6
The treatment of IE has traditionally been based on consensus
acquired during the years in which the majority of IE was due to
penicillin-sensitive streptococci, and few randomized clinical
studies have been conducted in the past. The appearance of S.
aureus tricuspidvalveendocarditis in intravenousdrugusers, againa
relatively easy-to-treat condition in the absence of resistance to the
very active anti-staphylococcal penicillins, has prompted a series of
trials aimed at deﬁning optimal treatment schedules. The appear-
ance of Gram-positive resistant and multi-resistant microorgan-
isms, together with the increasing number of patients with co-
morbidities, and of infection of prosthetic valves, has created new
problems and the need for more evidence. Many questions remain
unresolved: some, like the role of newantibiotics in the treatment of
resistant infections, are new; others, like the optimal duration of
treatment, the exact role of combination therapy with aminoglyco-
sides and cell-wall active antibiotics, or the efﬁcacy of glycopeptides
in the treatment of IE are old but unresolved, in the absence of
evidence from the literature. The role of traditional laboratory
diagnostic techniques, like the determination of serum bactericidal
activityandsynergy tests, aswell as the roleofnewer techniques like
therapeutic drug monitoring of plasma levels of antibiotics widely
used in the treatment of Gram-positive bloodstream infections, but
with a narrow therapeutic window, or whose optimal dosage in
critically ill patients is yet to be deﬁned, are likewise uncertain and
not supported by a great body of evidence.
The situation is also alarming in the setting of sepsis, one of the
most common causes of death in the developed world7 with an
estimated annual mortality rate of 30–50 deaths per 100 000
population.8 Therefore, the emergence of Gram-positive multi-
resistant bacteria potentially causing sepsis is of serious concern to
public health. Again, there is an urgent need to acquire sound
evidence on the optimal treatment of sepsis in the setting of
antibiotic resistance, and to evaluate the role of new drugs.
Finally, infections of vascular prostheses are severe infections
involving vascular grafts, whose treatment is made extremely
difﬁcult by the need to remove the infected material, generally a
life-sustaining implanted medical device, and for which very
scarce evidence exist as to the optimal medical or surgical
treatment.9 While some authors invoke the use of long-term
suppressive antibiotic therapy for the treatment of these condi-
tions,10 the introduction of new antibiotics active on resistant
strains offers new treatment opportunities; however very few data
are available on this issue.2. Objective
The aim of this studywas to review the literature on the optimal
treatment of severe bloodstream infections (sepsis, endocarditis,
and infections of vascular prostheses) caused by resistant Gram-
positive strains, with a special focus on studies on new antibiotics
against Gram-positive resistant microorganisms and new presen-
tation of Gram-positive infections.
3. Materials and methods
3.1. Controversial issues
A group of experts in the ﬁeld of bloodstream infections was
identiﬁed and enrolled in a faculty. The faculty was in charge of
deﬁning controversial issues, developing a search strategy, and
reviewing the retrieved literature in order to obtain data on
controversial issues and to draw recommendations based on the
best available evidence. After discussionwith the facultymembers,
the following controversial issues were deﬁned:
 Role of aminoglycosides and teicoplanin in the treatment of
resistant Gram-positive bacterial endocarditis.
 Optimal duration of treatment of resistant Gram-positive
bacterial endocarditis.
 Optimal use of the new antibiotics (quinupristin/dalfopristin,
daptomycin, linezolid, tigecycline) in the treatment of blood-
stream infections caused by resistant Gram-positive strains.
 Use ofmicrobiological techniques (i.e., bactericidal serum testing
and synergy testing) and of pharmacokinetic data (e.g.,
monitoring of plasma levels of antibiotics) in the treatment of
difﬁcult-to-treat Gram-positive bloodstream infections.
For each controversial issue, one ormore structured new issues,
in the form of a query, were created to obtain a series of
unambiguous queries on the basis of which to create appropriate
strings to optimize high quality literature searches. In other words,
the stringswere to be optimized to retrieve comparative studies on
the topics of interest.
Firstly, the issues were divided in two distinct areas (therapeu-
tic and diagnostic/laboratory monitoring).
For the therapeutic area, the following new queries were
created:
1. In the treatment of infective endocarditis caused by Gram-
positive microorganisms, is combination therapy with an
aminoglycoside plus another antibiotic more effective than
monotherapy?
2. In the treatment of infective endocarditis caused by Gram-
positivemicroorganisms, is therapywith an aminoglycoside in a
single daily dose more effective than therapy in three divided
doses?
3. In the treatment of infective endocarditis caused by Gram-
positive microorganisms, is therapy with teicoplanin as effec-
tive, and associated with fewer adverse events, than therapy
with vancomycin?
4. In the treatment of infective endocarditis caused by Gram-
positive microorganisms, what is the optimal duration of
treatment?
5. In the treatment of infective endocarditis caused by multi-
resistant Gram-positive microorganisms, is therapy with
quinupristin/dalfopristin, linezolid, daptomycin, and tigecycline
effective?
6. In the treatment of sepsis caused by multi-resistant Gram-
positive microorganisms, is therapy with quinupristin/dalfo-
pristin, linezolid, daptomycin, and tigecycline effective?
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multi-resistant Gram-positive microorganisms, is therapy with
quinupristin/dalfopristin, linezolid, daptomycin, and tigecycline
effective?
For the diagnostic/laboratory monitoring area the following
new queries were created:
1. In the treatment of infective endocarditis caused by multi-
resistant Gram-positive microorganisms, is monitoring of
plasma levels of vancomycin, gentamicin, and teicoplanin
effective in reducing adverse events and costs, and in increasing
treatment efﬁcacy?
2. In the treatment of infective endocarditis caused by multi-
resistant Gram-positive microorganisms, is the use of serum
bactericidal and synergy testing (alongwith traditionalmethods
such as minimum inhibitory concentration (MIC) determina-
tion) effective in reducing adverse events and costs, and in
increasing treatment efﬁcacy?
3.2. Literature search and study selection
A series of inclusion criteria for the studies was then deﬁned for
each query: population studied, type of intervention, comparator
or confrontation, type of outcome, and deﬁnition of the type of
studies to be retrieved. In general it was decided to restrict the
search to the adult population, to consider primary outcomes (such
as cure or mortality), and to limit the search to randomized
controlled studies or other comparative studies. Animal studies, as
well as studies limited to pharmacokinetic/pharmacodynamic
analysis, were excluded. No restrictions on year of publication or
language were introduced. In some cases, however, the strategy
was modiﬁed and made less restrictive because (as in the case of
new antibiotics) very few randomized or comparative studieswere
obtained. As a rule, the use ofMeSH termswas preferred; to delimit
the search the ‘limits’ function of PubMed was used. For each
query, different research strategies were tried, and the one
considered more effective (maximum of high quality studies
retrieved with minimum non-pertinent material) was eventually
chosen. The research was mainly conducted on the PubMed
(MEDLINE) database, and completed with hand searching of
references of retrieved studies and of other material obtained from
web sites of scientiﬁc societies such as the American Heart
Association and the Infectious Diseases Society of America. ForTable 1
Quality evaluation of evidence according to the GRADE Working Group method
Study Study
design
Study
limits
Consistency Directness Accu
Fowler (21) 4 – – 1 1
Rehm (22) 4 – – 1 1
Shorr (47) 3 – – – –
Stevens (48) 4 1 – – –
Wilcox (49) 4 2 – – 1
Wilcox (50) 4 2 – – 1
Cepeda (51) 4 – – 1 –
Adembri (52) 4 1 – – –
Linden (53) 2 – – – –
Abrams (16) 4 1 1 – –
Sexton (19) 4 1 – – –
Ribera (15) 4 1 – – –
Cosgrove (20) 3 – – – –
Gilbert (17) 4 – – – –
Huang (18) 3 – – – –
Fortu´n (13) 4 1 – – –
Fortu´n (14) 4 1 – – –
Ferna´ndez de Gatta (55) 4 1 – 1 –
Welty (56) 2 – – 1 –
Note: the minimum score which can be assigned to each evidence is 1.each retrieved study a schematic report, based on a pre-deﬁned
form, was created.
After this phase, the obtained results were discussed with the
group members. As for some issues the number of high quality
studies obtained was too scarce, it was agreed to conduct a new
literature search aimed at obtaining case reports, and to include
cases from personal series of the faculty members. Minimum
requirements for cases to be included in the evaluation were
completeness and quality of exposition. Retrieved single case
reports or case series were summarized on a pre-deﬁned form.
Case reports were searched for queries 5 and 7 in the therapeutic
area (use of new antibiotics in the treatment of endocarditis and
infections of vascular prostheses) using a new, unrestricted
research strategy, which included only the MeSH term or generic
name of the drug. The case reports to be included in the ﬁnal
collection were chosen after reading titles and abstracts. For query
7 (infections of vascular prostheses), only one case reporting
treatment with the new antibiotics was retrieved; it was therefore
decided to retrieve case reports describingmodalities of treatment
of infected vascular prostheses.
3.3. Classiﬁcation and evaluation of selected evidence
The quality of the studies was then assessed. The methodologi-
cal quality of randomized controlled trials and of non-randomized
studies was assessed with the CONSORT method and Newcastle–
Ottawa Quality Assessment Scale, respectively, while for case
reports and case series the quality was assessed on the basis of a
structured checklist.
Finally, the studies and case series/reports retrieved for each
query were analyzed to draw draft recommendations, with the
strength of each statement deﬁned according to the GRADE score
of the studies retrieved for that issue.11 The results and the draft
were then re-discussed with the faculty, and afterwards in an
enlarged group that included a panel of experts in the ﬁeld; as a
result, those queries for which there were insufﬁcient data or non-
convincing evidence to draw a recommendation were eventually
eliminated from the ﬁnal recommendations. These recommenda-
tions were presented and voted for during a national conference in
which physicians involved in the treatment of these conditions had
convened.
The queries with the inclusion criteria, the search strings, and
the ﬂow charts with details of the results of the research for each
query are presented in the Appendix. The results of each search,racy Bias Association
evidence
Dose/response
gradient
Confounder
bias
Total quality
score
– – – – 2
– – – – 2
1 – – – 2
1 – – – 2
1 – – – 1
1 – – – 1
- – – – 3
1 – – – 2
- – – – 2
1 – – – 1
1 – – – 2
1 – – – 2
1 – 1 – 3
1 – – – 3
1 – – – 2
1 – – – 2
1 – – – 2
– – – – 2
– – – – 1
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deﬁned forms for the collection of case reports, and a schematic
form for each retrieved study and case report are available on
request from the group coordinator. The quality evaluation of the
evidence obtained from comparative studies according to the
GRADEWorking Groupmethod is presented in Table 1. The details
of the methodology are reported in this supplement.12
4. Results
4.1. Therapeutic area – queries 1–4
1. In the treatment of infective endocarditis caused by Gram-
positive microorganisms, is combination therapy with an
aminoglycoside plus another antibiotic more effective than
monotherapy?
2. In the treatment of infective endocarditis caused by Gram-
positivemicroorganisms, is therapywith an aminoglycoside in a
single daily dose more effective than therapy in three divided
doses?
3. In the treatment of infective endocarditis caused by Gram-
positive microorganisms, is therapy with teicoplanin as effec-
tive, and associated with fewer adverse events, than therapy
with vancomycin?
4. In the treatment of infective endocarditis caused by Gram-
positive microorganisms, what is the optimal duration of
treatment?
For these four queries a single research was conducted, i.e., a
single, generic string was used for the MEDLINE search and the
results were then reﬁned manually.
4.1.1. Comparative studies
Eight comparative studies were retrieved. In one study by
Fortu´n et al.,13 conducted on a small population of intravenous
drug users, teicoplanin was compared to cloxacillin + gentamicin
in right-sided endocarditis caused by methicillin-susceptible S.
aureus (MSSA); the results in the teicoplanin arm (at a dosage of
10 mg/kg/12 h for the ﬁrst 3 days, 6 mg/kg/12 h for the following 4
days, and then 7 mg/kg/24 h for 21 days) were signiﬁcantly worse,
with 7/8 (87.5%) cured in the cloxacillin + gentamicin group and
only 2/6 (33%) in the teicoplanin group. In another study, again by
Fortu´n et al.,14 the efﬁcacy and safety of a short course of a
combination of a glycopeptide (vancomycin or teicoplanin) and
gentamicin compared with a combination of cloxacillin and
gentamicin in the treatment of right-sided endocarditis caused
by S. aureus was assessed. The results in both glycopeptide arms
were inferior with respect to the cloxacillin + gentamicin arm (11/
11, 100% success in the cloxacillin/gentamicin arm, vs. 6/10, 60%
success in the vancomycin arm and 7/10, 70% in the teicoplanin
arm); there were, however, no differences between teicoplanin (at
a dosage of 12 mg/kg/day) and vancomycin.
Ribera et al.15 compared the efﬁcacy of cloxacillin alone with
that of cloxacillin + gentamicin in the 2-week treatment of right-
sided S. aureus endocarditis in intravenous drug users. The results
in the combination arm were no better than those of the single
antibiotic arm (34/45, 76% success in the cloxacillin arm; 31/45,
69% in the combination arm). Abrams et al.16 compared single vs.
combination (i.e., with aminoglycoside) drug therapy of S. aureus
endocarditis in intravenous drug users; again, no differences were
noted between the two groups (i.e., no advantage of the
combination therapy).
Gilbert17 compared a higher teicoplanin dose, i.e., a 12 mg/kg
loading dose followed by 6 mg/kg/day, with a standard dose of
vancomycin of 30 mg/kg/day in the treatment of patients with
documented bacteremia due to Gram-positive cocci. A smallsubset of patients with infective endocarditis was present. Because
of the observed high failure rate in the teicoplanin arm, enrolment
was interrupted after 12 patients in order to conduct an interim
analysis. Even with the small numbers, the failure rate of
teicoplanin in patients with left-sided endocarditis almost
achieved statistical signiﬁcance (p = 0.07). The authors concluded
that the drug was a failure at the dosage regimen employed.
Huang andHsu18 retrospectively compared patientswithMRSA
endocarditis treated with teicoplanin (6–12 mg/kg) because of
intolerance or contraindication to vancomycin, and vancomycin.
There were no differences in the two groups. In the teicoplanin
group, mortality was 7/15 (47%), embolization 3/15 (20%), and
microbiological failure 6/15 (40%). while in the vancomycin group
the corresponding ﬁgures were 15/36 (42%), 6/36 (17%), and 13/38
(34%), respectively.
Sexton et al.19 compared two regimens, one with ceftriaxone
alone for 4 weeks, the other with a combination of ceftriaxone and
gentamicin as a single dose in patients with penicillin-susceptible
Streptococcus endocarditis. Both treatments were effective.
Microbiological success was obtained in 22/23 (95.7%) patients
in the ceftriaxone only arm and in 22/23 (95.7%) patients in the
combination arm. Cure without surgery was obtained in 21/26
(80%) patients in the ceftriaxone only arm and in 15/25 (60%)
patients in the combination arm.
Finally, in a recently published study by Cosgrove et al.20 the
safety data of a randomized, open trial comparing daptomycin and
standard therapy (either anti-staphylococcal penicillin or vanco-
mycin, plus initial gentamicin) in the treatment of bacteremia and
endocarditis caused by S. aureus were analyzed. The aim of the
study was to evaluate the clinical impact of initial low-dose
gentamicin on renal function. The population analyzed was that of
patients participating in the randomized trial comparing dapto-
mycin and standard anti-staphylococcal therapy published by
Fowler, presented in the next section. One-hundred twenty-two
patients received gentamicin in association with other antibiotics,
and were compared to a group of 100 not receiving gentamicin. A
decrease in creatinine clearance was observed in 27 (22%) patients
receiving gentamicin, as opposed to eight (8%) of those not
receiving gentamicin. A sustained 50% decrease of creatinine
clearancewas observed in seven (6%) and no patients, respectively,
and a sustained 25% decrease of creatinine clearance was observed
in 26 (21%) and nine (9%) patients, respectively. At multivariate
analysis, predictors of clinically signiﬁcant decrease in creatinine
clearance were age 65 years (odds ratio (OR) 3.56, conﬁdence
interval (CI) 1.66–7.65) and receipt of any dose of gentamicin,
either as part of the study treatment or as an initial low dose before
treatment (OR 3.39, CI 1.43–8.00). Though the study was not
projected to assess this point, the results show that even small
doses of gentamicin are associated with an increase in renal
toxicity in this patient population.
4.2. Therapeutic area – query 5
In the treatment of infective endocarditis caused by multi-
resistant Gram-positive microorganisms, is therapy with quinu-
pristin/dalfopristin, linezolid, daptomycin, and tigecycline effec-
tive?
4.2.1. Comparative studies
Two comparative studies were retrieved, both referring to a
randomized controlled trial that compared daptomycin vs.
standard therapy in the treatment of bacteremia and endocarditis
caused by S. aureus. The aim of this study was to test the non-
inferiority of daptomycin as compared to standard treatment. In
the study by Fowler et al.,21 235 adult patients with one or more
blood cultures positive for S. aureus infection were enrolled.
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gentamicin for the ﬁrst 4 days in left-sided endocarditis) or
standard therapy (vancomycin or anti-staphylococcal penicillin + -
gentamicin for the ﬁrst 4 days), in an unblinded fashion. The main
outcome was the clinical success rate in each of the two treatment
groups in the modiﬁed intention-to-treat population, assessed 42
days after the end of therapy. In the study population, 53/235
(22.5%) had infective endocarditis: of these, 9/28 (32%) in the
daptomycin group and 9/25 (36%) in the standard treatment group
were cured. Nineteen patients in the daptomycin group and 16 in
the standard treatment group had right-sided endocarditis. The
success rate for both groups was similar: 8/19 (42%) in the
daptomycin group and 7/16 (43%) in the standard treatment group.
Nine patients in the daptomycin group and nine in the standard
treatment group had left-sided endocarditis. In this small
subgroup, the failure rate was very high in both treatment arms:
one patient in the daptomycin group (11%) and two in the standard
treatment group (22%) were cured. Considering the entire
population of patients (endocarditis plus bacteremia), daptomycin
was associated with more microbiological failures, while standard
treatmentwas associatedwithmore failures due to adverse events,
though the differences did not reach statistical signiﬁcance.
In the study by Rehm et al.22 (a subset analysis of the Fowler
study), patients with endocarditis caused by MRSA (13 in the
daptomycin group and 10 in the standard treatment group) were
analyzed in detail. Of the 13 patients with MRSA infective
endocarditis in the daptomycin arm, 4/8 (50%) of those with
right-sided endocarditis and 0/5 of those with left-sided endocar-
ditis were cured; the same rates were obtained in the standard
treatment arm, with 3/6 (50%) of those with right-sided
endocarditis and 0/4 of those with left-sided endocarditis cured.
4.2.2. Case series
Falagas et al.23 reported a series of 33 patients with 34 episodes
of endocarditis treated with linezolid. Nineteen were male; the
median age was 66 years (range 0.5–80 years); co-morbidities
were present in the vast majority of cases (eight chronic renal
failure, eight diabetes, six cancer, four treatment with steroids, one
rheumatoid arthritis, one HIV infection). There were 27 episodes
on native valves, and seven involved prosthetic valves. The isolates
were vancomycin-intermediate S. aureus (VISA; 10 cases), MRSA
(eight cases), vancomycin-resistant Enterococcus spp (VRE; eight
cases), coagulase-negative staphylococci (CoNS; ﬁve cases),
Enterococcus faecalis (two cases), and Streptococcus mitis and
Corynebacterium striatum (one case each). Linezolid was adminis-
tered for a median of 42 days, associated in one third of cases with
other drugs (rifampin in ﬁve cases, gentamicin in four, fusidic acid
in three, amikacin in one). Eight patients underwent surgery. The
reported success rate was 63.6%, and the overall mortality 33%.
Mun˜oz et al.24 reported a series of nine cases of infective
endocarditis successfully treated with linezolid. They were six
males and three females, aged 57–82 years, with serious co-
morbidities (one cancer, three transplants). Five patients had a
prosthetic valve infection (three aortic, two mitral) and four a
native valve infection (two aortic, one mitral, one tricuspid). The
isolates were MSSA (four cases), MRSA (two cases), and E. faecalis,
Streptococcus mutans, and C. striatum in one case each. Patients
received linezolid 600 mg every 12 h for 2–4 weeks after failure of
previous antibiotic regimens. Four underwent surgery. The
reported success rate was 100%, with no deaths after a follow-
up of 7–31 months.
Falagas et al.25 reported a series of 19 patientswith endocarditis
treated with daptomycin. Nine were male; the median age was
60.5 years (range 13–92 years); co-morbidities were present in
two thirds of cases (three chronic renal failure, two diabetes, one
cancer, two systemic lupus erithematosus (SLE), three bonemarrow transplantation). There were 17 episodes on native valves
and two on prosthetic valves. The isolateswereMRSA (eight cases),
MSSA (ﬁve cases), VRE (three cases), and CoNS, E. faecalis, and C.
striatum in one case each. Daptomycin was administered for a
median of 28 days, associated in one half of cases with other drugs
(rifampin in three cases, gentamicin in three, minocycline and
linezolid, one case each). Data on surgery were not reported. The
reported success rate was 57.8% and the overall mortality 38.9%.
Howden et al.26 reported a series of patients with serious
infections caused by MRSA with reduced susceptibility to
vancomycin. Eight patients had infectious endocarditis. Median
age was 72.5 years (range 66–80 years). The majority of patients
had associated co-morbidities. Left-sided endocarditis was present
in ﬁve patients (mitral valve in two and aortic valve in three; two
were prosthetic aortic valves). The vancomycin MIC was 2 mg/ml
for ﬁve isolates and 4mg/ml for three isolates. Of these eight
patients, seven were treated with linezolid, in different schemes,
three of whom (42.8%) were cured.
4.2.3. Single case reports
Sgarabotto et al.27 reported a case of successful treatment of an
MRSA aortic valve endocarditis with the combination of vanco-
mycin and quinupristin/dalfopristin. Arias et al.28 adopted with
success an unusual drug combination – daptomycin at 9 mg/
kg + ampicillin + gentamicin for 6 weeks – after the failure of
daptomycin monotherapy at the usual dosage for a mitral valve
infectious endocarditis caused by vancomycin-resistant Entero-
coccus faecium. The patient experienced mild dizziness, which was
attributed to the prolonged exposure to the aminoglycoside, but no
renal adverse events were reported.
Cunha et al.29 reported clinical success with high-dose (12 mg/
kg) daptomycin in a case of bacteremia and probable endocarditis
caused by a vancomycin-tolerant E. faecalis. Cunha et al.30 also
reported an unusual case of a patient with Job’s syndrome and
MRSA meningitis who had failed a regimen of vancomycin + cef-
triaxone + ampicillin. A diagnosis of mitral valve endocarditis was
eventually made and the patient was successfully treated with a
combination of high dose daptomycin (12 mg/kg) and linezolid. No
adverse events were reported after an 8-week course.
Matsumura and Simor31 reported clinical success in a case of
aortic valve endocarditis caused by a vancomycin-resistant E.
faecium strain. The patient had failed a 2-week course of
quinupristin/dalfopristin but responded to an association of
quinupristin/dalfopristin + doxycycline + rifampin for 8 weeks. In
this case, serum bactericidal testing showed the absence of activity
of single drugs, while synergy testing showed that the association
was synergistic.
Viale et al.32 reported a case of successful treatment of MRSA
mitral valve endocarditis with quinupristin/dalfopristin followed
by oral linezolid. Zinkernagel et al.33 reported an unusual severe
and destructive form of endocarditis due to Staphylococcus
epidermidis. Clinical success was achieved with a combination of
antibiotics (vancomycin, quinupristin/dalfopristin, levoﬂoxacin)
plus cardiac surgery. Konstantinov and Zehr34 reported a case of
aortic valve endocarditis caused by a vancomycin-resistant E.
faecium treated with success with a combination of quinupristin/
dalfopristin, rifampin, and doxycycline and aortic valve replace-
ment. Mergenhagen and Pasko35 described a case of successful
treatment of left-sided endocarditis caused by community-
acquired MRSA with the association daptomycin/rifampin and
mitral repair; data on follow-up are, however, lacking.
Chesi et al.36 reported clinical success with quinupristin/
dalfopristin in a patient with MRSA tricuspid valve endocarditis
complicated by septic pulmonary emboli, after failing sequential
treatment with teicoplanin–co-trimoxazole and linezolid associ-
ated to vancomycin–rifampin–co-trimoxazole. Liu et al.37 reported
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the presence of a Hickman’s catheter and deﬁbrillator, in which
treatment with daptomycin failed. The patient was successfully
treated with linezolid/fusidic acid and then teicoplanin. In this
case, the failure of daptomycin and the success of the combination
regimen with linezolid was attributed to the appearance of
pulmonary emboli during treatment with daptomycin.
Tenover et al.38 reported the development of daptomycin
resistance in an S. aureus isolate with hetero-resistance to
vancomycin, during treatment for left-sided endocarditis. In this
case, cure was achieved with linezolid. Babcock et al.39 described a
case of VRE infection of the tricuspid (and perhaps aortic) valve
successfully treated with linezolid after failure of quinupristin/
dalfopristin. The patient, a woman with Down syndrome and
mental retardation, completed the 6-week course of treatment
with oral linezolid.
Sakoulas et al.40 reported a case of mitral valve endocarditis
failing to respond to daptomycin because of acquisition of
resistance during treatment. The patient was infected with an
MSSA strain, but failed a standard regimen with gentamicin/
nafcillin; a short course of treatment with vancomycin had also
been administered before blood culture results. After switching to
daptomycin, a progressive increase in theMIC (from 0.125 to 2mg/
ml) was noted. The patient was eventually cured with surgery and
a combination of nafcillin and gentamicin.
Schwartz et al.41 reported a case of failure of sequential
antibiotics in a mitral valve endocarditis caused by a vancomycin-
resistant E. faecium. The patient was sequentially treated with
linezolid, daptomycin 6 mg/kg, an association of daptomycin 8 mg/
kg + gentamicin + doxycycline, and quinupristin/dalfopristin
(which was associated with a transient negativity of blood
cultures). Synergy tests showed the absence of synergy for any
antibiotic combination. Serum bactericidal test showed the
absence of bactericidal or bacteriostatic activity while on
daptomycin 8 mg/kg.
Huang et al.42 described a patient who was admitted with fever
and treated for MRSA bacteremia. A diagnosis of mitral valve
endocarditis and septic thrombophlebitis was made 44 days after
admission. The patient received several antibiotic courses (among
which were vancomycin, teicoplanin, daptomycin, linezolid, and
fusidic acid) without effect, and eventually died of a Candida
sepsis. Several blood cultures were positive for MRSA, with the
emergence of daptomycin resistance during treatment.
Lemaire et al.43 reported a case of MRSA infection of the aortic
valve, unsuccessfully treated with several courses of antibiotics
(vancomycin, gentamicin, rifampin, daptomycin, linezolid, quinu-
pristin/dalfopristin, trimethoprim)whowas eventually cured after
aortic valve replacement. An increasedMIC for daptomycin (from 1
to 8) during treatment was reported. Chow et al.44 reported a case
of superinfection caused by E. faecalis during treatment with
quinupristin/dalfopristin of an MRSA endocarditis.
Pistella et al.45 reported a case of community-acquired MRSA
sepsis with endocardial and cerebral metastatic seeding who
developed coma with multiple cerebritis lesions under vancomy-
cin plus amikacin therapy. The patient was eventually cured with
the addition of linezolid to the initial antimicrobial regimen. Shah
and Murillo46 reported a case of C. striatum endocarditis that was
treated successfully with daptomycin plus rifampin for 6 weeks
following an unsuccessful attempt at vancomycin desensitization
and failure of linezolid therapy.
4.3. Therapeutic area – query 6
In the treatment of sepsis caused by multi-resistant Gram-
positive microorganisms, is therapy with quinupristin/dalfopris-
tin, linezolid, daptomycin, and tigecycline effective?4.3.1. Comparative studies
Seven comparative studies were retrieved. Shorr et al.47
retrospectively analyzed the results of ﬁve randomized controlled
studies comparing linezolid and vancomycin in the sponsor’s
database, in order to examine the outcomes in the subgroup of
patients (144/3228) with S. aureus bacteremia. The patients were
adults with pneumonia acquired within 48 h after hospital
admission, or complicated skin and soft tissue infections, or MRSA
infections, and the comparison was made between linezolid
600 mg twice daily and vancomycin 1 g twice daily. Linezolid was
administered intravenously for at least 7 days and could then be
changed to the oral formulation. Seventy-four patients (36 with
MRSA) were treated with linezolid and 70 (28 with MRSA) were
treated with vancomycin. Considered outcomes were cure of
primary infection, microbiological eradication of S. aureus bacter-
emia, and overall survival. Clinical cure was obtained in 28/51
(54.9%) patients treated with linezolid and 25/48 (52%) patients
treated with vancomycin (OR 1.12, 95% CI 0.51–2.47). Microbio-
logical eradication was obtained in 41/59 (69.5) patients treated
with linezolid and in 41/56 (73.2%) of those treated with
vancomycin (OR 1.00, 95% CI 0.47–2.12). Mortality was 19/74
(25.6%) in the linezolid arm and 18/70 (25.7%) in the comparator
arm (OR 1.00, 95% CI 0.47–2.12).
In the study by Stevens et al.,48 patients with presumed MRSA
infections were randomly assigned to linezolid, 600 mg twice
daily, or vancomycin, 1 g twice daily, both for at least 7 days, in an
unblinded fashion. Both clinical and microbiological outcomes
were considered. S. aureus bacteremia was present in 45/240
patients in the group randomized to linezolid and 40/220 in the
group randomized to vancomycin. In the intention-to-treat
analysis, cure was obtained in 17/33 (51.5%) bacteremic patients
treated with linezolid and in 15/32 (46.9%) bacteremic patients
treated with vancomycin.
Wilcox et al.49 described the results of an open-label,
randomized, multicenter study comparing the clinical efﬁcacy,
safety, and tolerance of linezolid with that of teicoplanin in
patients with suspected or proven Gram-positive infections,
including pneumonia, skin and soft tissue infections, right-sided
endocarditis, and bacteremia. Linezolid was given at a dose of
600 mg twice daily, while the dosage of teicoplanin was at the
discretion of the investigator. A clinical success (cure or improve-
ment of clinical condition) was reported in 23/26 (88%) bacteremic
patients treated with linezolid and in 17/30 (56%) bacteremic
patients treated with vancomycin; the 31.8% treatment advantage
was statistically signiﬁcant (p = 0.009, 95% CI 10.2–53.4).
In the randomized, open trial study, again by Wilcox et al.,50
linezolid 600 mg twice daily and vancomycin 1 g twice daily were
compared in a group of patients with complicated skin and skin-
structure infections and catheter-related bloodstream infections.
In the subgroup of patients with catheter-related infections,
catheter removal was required for enrolment. Considered out-
comes were microbiological and clinical success. The results in the
subgroup of patients with catheter-related bloodstream infections
showed a microbiological success in 82/95 (86.3%) patients in the
linezolid group and in 67/74 (90.5%) patients in the vancomycin
group. Clinical success in the two arms was obtained in 70/93
(75.3%) and 59/73 (80.8%), respectively.
Cepeda et al.51 reported the results of a double-blind, double-
dummy randomized trial comparing linezolid with teicoplanin in
the treatment of suspected or proven Gram-positive infections in
critically ill patients in two mixed medical–surgical, tertiary
referral intensive care units (ICUs). Patients received either
intravenous linezolid (600 mg/12 h) plus teicoplanin dummy
(one dose/12 h for three doses then every 24 h intravenously) or
teicoplanin (400 mg/12 h for three doses then 400 mg/24 h
intravenously) plus linezolid dummy (one dose/12 h intravenous-
Table 2
Summary of extraction of comparative studies on new antibiotics in the treatment of multi-resistant Gram-positive sepsis
ID Aim Study design Population Intervention Comparator Outcomes Num/Den (I) Num/Den (C) Quality Notes
Shorr
200547
Compare LNZ and
Vanco in
SA bacteremia
Retrospective
analysis of
5 RCT
144 pts from
5 studies
LNZ Vanco Cure;
microbiological
eradication
Cure: 28/51
Eradication: 41/59
Cure: 25/48
Eradication: 41/56
MRB Small numbers
with MRSA
Stevens
200248
Compare LNZ and
Vanco in presumed
MRSA infection
RCT open 85 pts with
bacteremia
from 104 sites
LNZ Vanco Cure;
microbiological
eradication
Cure: 17/33 (ITT) Cure: 15/32 (ITT) MRB Small numbers
with bacteremia
Wilcox
200950
Test non-inferiority
of LNZ vs. Vanco in
treating catheter-
related infections
RCT open 180 pts with
catheter-related
infections from
100 sites
LNZ+ catheter
removal
Vanco+ catheter
removal
Microbiological
eradication;
cure
Eradication: 82/95
Cure: 70/93
Eradication: 67/74
Cure: 59/73
HRB Different groups
of pts (skin and
soft tissue + catheter-
associated infections)
Difﬁcult to analyze
separately
Wilcox
200449
Compare clinical
efﬁcacy, safety and
tolerance of LNZ
with that of Teico
RCT open 56 pts (subgroup
with bacteremia)
from 50 sites
LNZ (600mg
q12h)
Teico (dose not
speciﬁed)
Cure;
microbiological
eradication;
safety
Cure: 23/26 Cure: 17/30 HRB Weak comparator;
deﬁnition of success
vague; presentation
of data confusing
Adembri
200852
Compare two different
modalities of LNZ
administration
(intermittent vs.
continuous infusion)
in critically ill septic
pts
RCT open 18 septic ICU pts LNZ (600mg
q12h)
LNZ 300mg i.v.
loading dose +900
continuous infusion
on day 1, followed
by continuous
infusion of 1200
mg/daily
Cure;
microbiological
eradication;
PK/PD
parameters
Cure: 7/9
Eradication: 6/9
Cure: 7/9
Eradication: 7/9
MRB Small number of pts
Cepeda
200451
Compare LNZ with
Teico in the
treatment of
suspected or proven
Gram-pos infections
in critically ill pts
RCT double-
blind, double-
dummy
202 pts in two
mixed medical–
surgical, tertiary
referral ICUs
LNZ (600
mg/12 h)
plus
Teico dummy
Teico (400 mg/12 h
for 3 doses then
400 mg/24 h i.v.)
plus LNZ dummy
Microbiological
eradication;
cure
Clinical outcome:
71/100 success
(EOT)
40/100 success
(LTFU) Eradication:
49/70 (EOT)
Clinical outcome:
67/100 success (EOT)
35/102 success
(LTFU) Eradication:
45/68 (EOT)
LRB Good design of the
study; no differences
seen in the two
groups
Linden
199753
Verify efﬁcacy of Q/D
in the treatment of
VREF serious
infections
Case–control 62 pts with VREF
infection
Q/D Other antibiotics
(Vanco, b-lactams,
ciproﬂoxacin,
amino-glycosides)
Recurrent
bacteremia;
in-hospital
mortality;
VREF-associated
mortality
Recurrent
bacteremia 5/20
In-hospital
mortality 13/20
VREF-associated
mortality 5/20
Recurrent
bacteremia 21/42
In-hospital
mortality 22/42
VREF-associated
mortality 17/42
LRB Better microbiological
results not associated
with better survival
Num/Den (I), numerator/denominator for intervention group; Num/Den (C), numerator/denominator for control group; LNZ, linezolid; Vanco, vancomycin; Teico, teicoplanin; Q/D, quinopristin/dalfopristin; pts, patients; RCT,
randomized controlled trial; LRB, low risk of bias; HRB, high risk of bias;MRB,medium risk of bias;MRSA,methicillin-resistant Staphylococcus aureus; SA, Staphylococcus aureus; VREF, vancomycin-resistant Enterococcus faecium; ITT,
intention to treat; EOT, end of treatment; LTFU, long-term follow up; q12h, every 12hours; ICU, intensive care unit; i.v., intravenous; PK/PD, pharmacokinetic/pharmacodynamic.
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success rates were 71/100 (71%) and 49/70 (70%), respectively, in
the linezolid arm and 67/100 (67%) and 45/68 (66%) in the
teicoplanin arm. In the long-term follow-up, a clinical success was
reported in 40/100 (40%) of patients in the linezolid arm and in 35/
102 (34%) in the teicoplanin arm.
Adembri et al.52 reported the results of a randomized, open-
label study comparing two different modalities of linezolid
administration (intermittent vs. continuous infusion) in critically
ill septic patients (septic ICU patients with a microbiologically
documented infection caused by either glycopeptide-resistant or
glycopeptide-sensitive Gram-positive strains, but with no clinical
improvement after 5 days of glycopeptide therapy). Patients were
randomly assigned to receive linezolid 600 mg every 12 h as a 30-
min intermittent infusion (standard), or as a continuous infusion of
1200 mg/day (after a ﬁrst 300 mg loading dose administered as a
30-min infusion). Outcomes were clinical cure, microbiological
eradication, and pharmacokinetic/pharmacodynamic (PK/PD)
parameters. Nine patients were enrolled in each arm. Clinical
cure was obtained in 7/9 (77%) patients in both arms. Microbio-
logical eradication was obtained in 6/9 (66%) patients in the
intermittent group and in 7/9 (77%) in the continuous infusion
group.
Linden et al.53 reported the results of a case–control study on
the use of quinupristin/dalfopristin in adult patients with
bacteremia caused by vancomycin-resistant E. faecium (vancomy-
cin MIC 8 mg/l, teicoplanin MIC 8 mg/l, in vitro resistance to all
other appropriate agents, and quinupristin/dalfopristin MIC 2 mg/
l). All patients with vancomycin-resistant E. faecium bacteremia
before the availability of quinupristin/dalfopristin (January 1991–
December 1993)were considered the historical control cohort. The
intervention group (20 patients) was treated with quinupristin/
dalfopristin administered intravenously at 7.5 mg/kg every 8 h.
The 42 patients in the control group received other antibiotics
according to standard of care (vancomycin, b-lactams, ciproﬂoxa-
cin, aminoglycosides). The main considered outcomes were
recurrent bacteremia and in-hospital mortality. Recurrent bacter-
emia was lower in the intervention group (5/20, 25%) than in the
comparator group (21/42, 50%; p = not signiﬁcant), but in-hospital
mortality was similar (intervention group: 13/20, 65%; control
group: 22/42, 52%).
A summary of these studies is reported in Table 2.
4.4. Therapeutic area – query 7
In the treatment of infections of vascular prostheses caused by
multi-resistant Gram-positive microorganisms, is therapy with
quinupristin/dalfopristin, linezolid, daptomycin, and tigecycline
effective?
4.4.1. Comparative studies
Only one comparative study was retrieved, on a subset of
patients from the study by Fowler et al. on daptomycin,54 already
presented in the results of query 1. The subset was composed of 38
patients with intravascular devices comprising both removable
and non-removable catheters and vascular prostheses (pacemak-
er/deﬁbrillators, coronary stents, tunneled catheters, abdominal
aortic synthetic grafts, inferior vena cava ﬁlter, transjugular
intrahepatic portosystemic shunt, intra-aortic balloon pump). As
a group, no differences were noted in the two arms; 8/17 (47%)
patients in the daptomycin arm and 9/21 (43%) in the standard
treatment arm were deﬁned as clinical success. Overall success
was higher when antibiotic therapy was associated with removal
of the device. In the case of pacemakers/deﬁbrillators, a clinical
successwas obtained in 3/5 caseswhen the devicewas removed, as
compared to 0/6 cases when the device was left in place. Thedifferences were less clear in the case of tunneled catheters
(success in 4/8 following device removal and in 2/3 when the
device was left in place). The numbers however were too small for
deﬁnitive conclusions.
4.5. Diagnostic/laboratory monitoring area – query 1
In the treatment of infective endocarditis caused by multi-
resistant Gram-positive microorganisms, is monitoring of plasma
levels of vancomycin, gentamicin, and teicoplanin effective in
reducing adverse events and costs, and in increasing treatment
efﬁcacy?
4.5.1. Comparative studies
Two comparative studies were retrieved. One study by
Ferna´ndez de Gatta et al.55 evaluated the cost-effectiveness of
vancomycin serum concentration monitoring in patients with
hematological malignancies. In this randomized, unblinded clini-
cal trial, patients with hematological malignancies and Gram-
positive infection requiring treatment with vancomycin were
randomized to two groups; in one, treatment was modiﬁed
according to therapeutic drug monitoring (TDM) of vancomycin
with the active intervention of a clinical pharmacist, while in the
other group TDM was not performed. Both clinical and economic
outcomes were considered. A greater incidence of nephrotoxicity
was observed in the group not receiving TDM. Logistic regression
analysis conﬁrmed that TDM independently reduced the incidence
of nephrotoxicity in this patient population. On the basis of this
reduced nephrotoxicity, an incremental cost of US$ 435 per case of
nephrotoxicity prevented was found for vancomycin serum
concentration monitoring. The procedure appeared to be cost-
effective. The study however did not classify patients according to
type of infection (e.g., sepsis, endocarditis), so the results are not
generalizable to the population of patients with endocarditis.
In another study by Welty and Copa,56 patients were
randomized to receive or not vancomycin TDM. The study was
supported by a TDM pharmacist. TDM of vancomycin was
associated with fewer episodes of renal failure (7/61, 11.4% in
the TDM arm vs. 24/55, 43.6% in the non-TDM arm), decreased
length of therapy (11.1  5.8 days vs. 13.4  13.6 days), and possibly
reduced length of stay (36.8  30.4 days vs. 44.5  51.4 days). Only
two patients (both in the non-TDMgroup) had endocarditis, so results
are not immediately generalizable to this subgroup of patients.
4.6. Diagnostic/laboratory monitoring area – query 2
In the treatment of infective endocarditis caused by multi-
resistant Gram-positive microorganisms, is the use of serum
bactericidal and synergy testing (along with traditional methods
such as MIC determination) effective in reducing adverse events
and costs, and in increasing treatment efﬁcacy?
4.6.1. Comparative studies
No comparative studies were retrieved.
4.6.2. Single case reports
Matsumura and Simor31 reported a case of VRE aortic valve
endocarditis in which time-kill synergy studies and serum
bactericidal testing were used to test an association of quinupris-
tin/dalfopristin + doxycycline + rifampin. Serumbactericidal testing
showed the absence of activity of single drugs,while synergy testing
showed that the association was synergistic. The patient received
this treatment for 8 weeks and the outcome was successful.
Schwartz et al.41 reported another case of endocarditis caused by
a vancomycin-resistant E. faecium, in which serum bactericidal
testing and synergy testing were used to guide treatment. After
Recommendations
In the treatment of native valve MSSA infectious endocardi-
tis, there is no convincing evidence of the usefulness of a
combination of gentamicin with either vancomycin or an anti-
staphylococcal penicillin, while there is evidence that this
combination is associated with an increase in toxicity,
especially in patients aged over 65 years. Gentamicin in this
condition must therefore be used with caution (B). In the
treatment of native valve IE caused by MRSA there is limited
evidence on the utility of combination therapy (D). The use of
E. Boumis et al. / International Journal of Infectious Diseases 14S4 (2010) S23–S38 S31failure of various regimens, an association of daptomycin 8 mg/
kg + gentamicin + doxycycline was tried. Synergy tests showed the
absence of synergy for any antibiotic combination, while serum
bactericidal tests at a dilution of 1:2 showed the absence of
bactericidal or bacteriostatic activitywhile on daptomycin 8 mg/kg.
4.7. From the evidence to the recommendations
After thorough revision of the retrieved studies, four queries
were eliminated because of paucity of data: three from the
therapeutic area (regarding the administration of aminoglycosides
in single or fractioned doses, the optimal duration of treatment in
IE, and the use of new antibiotics in the treatment of infections of
vascular prostheses) and one from the diagnostic/laboratory
monitoring area (on the use of serum bactericidal and synergy
testing). Therefore, the following discussion is limited to the ﬁve
queries for which comparative studies and other evidence allowed
the drawing up of recommendations.
4.8. Therapeutic area
4.8.1. Query 1
In the treatment of infective endocarditis caused by Gram-
positive microorganisms, is combination therapy with an ami-
noglycoside plus another antibiotic more effective than mono-
therapy?
The use of gentamicin (or other aminoglycosides) in association
with cell-wall active antibiotics has long been a mainstay of
therapy for severe infections, and it is still recommended in the
treatment of endocarditis due to E. faecalis, where the combination
of ampicillin and gentamicin is synergistic. The use of combination
therapy in infectious endocarditis caused by S. aureus and other
Gram-positive microorganisms is, however, less well founded, and
based more on theoretical considerations and animal experiments
than clinical evidence. Moreover, aminoglycosides are potentially
nephro- and ototoxic, and their use requires monitoring of plasma
levels of antibiotics.
Few comparative studies have tried to assess whether
combination therapy with aminoglycosides in the treatment of
Gram-positive IE is better than single therapy. Abrams et al16
(GRADE score 1) compared single vs. combination (i.e., with
aminoglycoside) drug therapy of S. aureus endocarditis in
intravenous drug users in a randomized, open trial. The
considered outcomes were time to defervescence, bacteriological
failure, congestive heart failure, surgery, and mortality. There
were no differences in the two groups, and mortality was
uniformly low. Ribera et al.15 (GRADE score 2) compared the
efﬁcacy of cloxacillin alone with that of cloxacillin plus gentami-
cin for the 2-week treatment of right-sided S. aureus endocarditis
in intravenous drug users in a randomized, open trial. Again, there
were no differences in the two groups. In another randomized,
open trial, Sexton et al.19 (GRADE score 2) compared two
antibiotic regimens (ceftriaxone alone for 4 weeks or ceftriax-
one + gentamicin for 2 weeks) for the treatment of adults with
penicillin-susceptible Streptococcus endocarditis. No differences
in themicrobiological success were found, while more patients in
the combination therapy arm were cured with surgery. These
three studies, all showing no advantage of combination therapy,
are limited by their open design and by the paucity of data on
randomization; moreover, they were mainly conducted on
populations of patients with a low mortality risk, so generaliza-
tion to other groups of patients is uncertain.
More recently, Cosgrove et al.20 (GRADE score 3) studied the
clinical impact of initial low-dose gentamicin on renal function in a
group of patients treated for S. aureus infective endocarditis or
bacteremia. The patients were enrolled in a randomized, open trialcomparing daptomycin and standard anti-staphylococcal therapy
in the treatment of bloodstream infections caused by S. aureus.
Patients in the standard treatment arm were treated with an
association of an anti-staphylococcal antibiotic (either vancomycin
or an anti-staphylococcal penicillin) and gentamicin, while
patients in the daptomycin arm received gentamicin if they had
left-sided endocarditis. The trial was not designed to assess the
effect of gentamicin on renal dysfunction, and the effect of
gentamicin on clinical outcome was not assessed. Nevertheless,
the results of this study show that small initial doses of gentamicin
are also signiﬁcantly associated with a decrease in renal function.
In summary, the limited available evidence shows that
aminoglycosides are not useful in the treatment of Gram-positive
infectious endocarditis in low-risk populations (i.e., drug addicts
with tricuspid valve S. aureus endocarditis and patients with
endocarditis caused by susceptible strains of Streptococcus). There
is also evidence that even short courses of aminoglycosides in the
treatment of S. aureus bloodstream infections are associated with
renal toxicity.4.8.2. Query 3
In the treatment of infective endocarditis caused by Gram-
positive microorganisms, is therapy with teicoplanin as effective,
and associated with fewer adverse events, than therapy with
vancomycin?
Few studies compared vancomycin and teicoplanin in the
treatment of infectious endocarditis. Gilbert et al.17 (GRADE score
3) published the results of a randomized, double-blind study
comparing a higher teicoplanin dose, i.e., a 12-mg/kg loading dose
followed by 6 mg/kg/day, with a standard dose of vancomycin of
30 mg/kg/day in the treatment of patients with documented
bacteremia due to Gram-positive cocci. The patients in the
teicoplanin arm received it at a dose of 6 mg/kg every 12 h for
three doses and then 6 mg/kg alternatingwith placebo every 12 h. A
small subset of patients had infectious endocarditis. The enrolment
was interruptedbecauseof a high failure rate in the teicoplanin arm.
The interim analysis showed that the failure rate of teicoplanin in
patients with left-sided endocarditis almost achieved statistical
signiﬁcance (p = 0.07), and the authors concluded that teicoplanin at
thisdosage isnot effective in the treatmentof left-sidedendocarditis
caused by Gram-positive microorganisms.
Huang and Hsu18 (GRADE score 2) studied 51 patients with
MRSA endocarditis (only deﬁnite cases according to Duke’s
criteria) in a retrospective, comparative study directly comparing
teicoplanin and vancomycin in the treatment of IE. No differences
emerged between the two treatment groups.
In the study by Fortu´n et al.14 (GRADE score 2), patients with
right-sided S. aureus endocarditis were randomly assigned in an
open way to three arms: cloxacillin plus gentamicin; vancomycin
plus gentamicin; and teicoplanin (12 mg/kg, given every 24 h, with
combination therapy is still indicated in the treatment of
prosthetic valve S. aureus endocarditis (D).
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The results in the group treated with teicoplanin and vancomycin
were comparable, but results in both arms were inferior to the
results in the cloxacillin arm. There is some additional evidence
demonstrating the inferiority of glycopeptides in the treatment of
endocarditis caused by susceptible strains of S. aureus. The same
author13 (GRADE score 2) compared teicoplanin at decreasing
doses (10 mg/kg/12 h for the ﬁrst 3 days, followed by 6 mg/kg/12 h
for 4 days, and 7 mg/kg/24 h for 21 days) vs. cloxacillin plus
gentamicin in intravenous drug users with right-sided S. aureus IE.
The cure rate was only 33% in the teicoplanin group as opposed to
87.5% in the cloxacillin/gentamicin group.
In conclusion, in the treatment of Gram-positive infectious
endocarditis there is limited evidence that teicoplanin is inferior to
vancomycin in the treatment of left-sided IE caused by Gram-
positive microorganisms, while in right-sided endocarditis caused
by MRSA, teicoplanin and vancomycin achieve similar results. It
must be remembered, however, that both drugs are inferior with
respect to anti-staphylococcal penicillins in the treatment of MSSA
endocarditis.Recommendations
Teicoplanin can be considered equivalent to vancomycin in
the treatment of right-sided endocarditis (D). In the treatment
of left-sided endocarditis, teicoplanin was inferior to vancomy-
cin when used at a loading dose of 6 mg/kg every 12 h for three
doses and then 6 mg/kg/day. In the treatment of left-sided
endocarditis the use of teicoplanin at higher dosages, though
common, is not supported by clinical evidence (D). Both drugs4.8.3. Query 5
In the treatment of infective endocarditis caused by multi-
resistant Gram-positive microorganisms, is therapy with quinupris-
tin/dalfopristin, linezolid, daptomycin, and tigecycline effective?
Only two randomized studies, both on daptomycin, were found,
one by Fowler et al.21 (GRADE score 2) and the other byRehmet al.22
(GRADE score 2). Both refer to a randomized controlled trial
comparing daptomycin to standard therapy in the treatment of
bacteremia and endocarditis caused by S. aureus. Daptomycin was
usedat a doseof 6 mg/kg. Theoverall success ratewas reported tobe
around 43% in the treatment of right-sided infectious endocarditis, a
rate comparable to standard treatment. Failures in the daptomycin
group were more commonly secondary to microbiological failure,
while those in the control groupweremore commonly secondary to
toxicity (mainly renal toxicity). The success rate in the treatment of
left-sided endocarditis was very low for both treatment arms. In the
subgroup of patients withMRSA, the success rate was 50% for right-
sided endocarditis and 0% for left-sided endocarditis. Surgical
treatment is reported in 2/9 patients with left-sided endocarditis in
the daptomycin group and 1/9 patients with left-sided endocarditis
in the standard treatment group, but no additional data on the
outcome are given. This study adopted a very strict deﬁnition of
success,with failureofobtainingabloodcultureat42daysof follow-
up considered as a clinical failure.
No randomized studies were found addressing the role of
quinupristin/dalfopristin, linezolid, and tigecycline in the treat-
ment of infectious endocarditis.
A series of cases (single case reports and case series) describing
the use of these antibiotics in the treatment of infective endocarditis
caused by multi-resistant Gram-positive microorganisms were
found.
are inferior to anti-staphylococcal penicillin when the strain of
S. aureus is susceptible to methicillin (C).Daptomycin
Falagas et al.25 (GRADE score 1) reported a series of 19 patients
with endocarditis treatedwithdaptomycin. Inﬁve of them(26%) the
cause was MSSA, while the remaining 14 cases were caused by
multi-resistant or difﬁcult-to-treat Gram-positive microorganisms
(MRSA 8/19, 42%; VRE 4/19, 21%; CoNS, E. faecalis, C. striatum one
case each). No growth was reported in one case. The left side of the
heart was involved in 13 cases and the right side in four; also
reported were infection of the aortic arch and of a pacemaker wire,
while for one case no description of the involved valve was given.
Data on surgery were not reported. The reported success rate was
57.8% and the overall mortality 38.9%. Eight out of 13 (61.5%)
patientswith left-sided IEwere considered cured, as compared to 2/
4 (50%) of those with right-sided IE. The relatively high success rate
in left-sided endocarditis is in contrast with the results of the
randomized controlled trial21 in which the success rate in left-sided
IEwas close to zero, but the high risk of bias inherent to case reports
must be considered, such as reporting bias (exclusion of failures
fromreporting) and incompletenessof reporting. For example, in the
series published by Falagas, in the majority of cases an adequate
follow-upwasnot reported, data crucial for thedetermination of the
realoutcome inpatientswith IE. In the randomizedtrial, on theother
hand, the deﬁnition of cure was stringent, with failure to obtain a
blood culture during follow-up considered as a clinical failure; this
can partially account for the marked differences in the outcome of
left-sided IE treated with daptomycin in the different types of
studies. All patients but three were treated with the standard dose
(6 mg/kg), and in six cases side effects were reported: elevation of
creatine kinase in four cases, renal failure in one case, and
eosinophilic pneumonia in one case.
Of the single case reports, some reported a clinical success with
daptomycin, alone or in combination with other antibiotics, in the
treatment of infectious endocarditis, while other reported failure.
Of nine reported single cases of treatment of IE with daptomycin,
three28,29,35 (GRADE score 1 for each) reported a clinical success. In
two cases, daptomycin was used at a higher dosage (9 mg/kg and
12 mg/kg, respectively), and in combination with other antibiotics
(ampicillin + gentamicin in one case, linezolid in the other). Of
note, in one case, failure with daptomycin alone at the standard
dose of 6 mg/kg was reported before the successful use of
combination therapy with a higher dose of daptomycin. The
mitral valve was involved in both cases; the offending organism
was VRE in one case and MRSA in the other. In the third case35
(GRADE score 1), successful treatment of left-sided endocarditis
caused by community-acquired MRSA with the association
daptomycin/rifampin and mitral repair was reported; data on
follow-up were, however, lacking.
Six reports described clinical failure of daptomycin in the
treatment of IE37,38,40–43 (GRADE score 1 for each). All but one were
left-sided IE. Inone caseofmitral valve endocarditis causedbyVRE40
daptomycin at a higher dose (8 mg/kg) in association with
gentamicin and doxycycline was used. Four authors38,40,42,43
(GRADE score 1 each) reported a progressive increase in the MIC
of daptomycin during treatment, associated with clinical failure.
Patients were infected with S. aureus and had previously been
treatedwithvancomycin, or the isolatewas resistant tovancomycin.
Finally, a quantityof unpublisheddata regarding the treatmentof
IE with daptomycin, mainly based on retrospective multicenter
observational studies, has recently been presented at an interna-
tional conference. The panel experts believe that the recommenda-
tionswill probablybe revised following thepublicationof thesedata.
In conclusion, in the treatment of right-sided S. aureus IE,
daptomycin is not inferior to the standard treatment, and it is
currently approved for this indication. The use of daptomycin to
treat left-sided endocarditis, at least at the standard dose (6 mg/kg)
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S. aureus infection pretreated with vancomycin or harboring
strains of S. aureus with hetero-resistance to vancomycin, loss of
activity of daptomycin during treatment must be considered.Recommendations
Daptomycin has been shown to be non-inferior to the
standard treatment in the treatment of right-sided Gram-
positive IE caused byMRSA (C) and can also be considered in the
treatment of right-sided IE caused by other Gram-positive
resistant strains (D)
In the treatment of left-sided IE, daptomycin alone at the
dosage of 6 mg/kg may be used, but the evidence supporting its
use is still scarce. The use of higher doses (up to 12 mg/kg) is a Recommendations
Linezolid canbeconsidered inselected cases for the treatment
of IE caused by Gram-positive resistant microorganisms, either
alone or in combination with other antibiotics (D). Linezolid can
also be used as an oral agent after an initial phase of intravenous
antibiotic therapy, but this indication needs further studies (D).
Owing to its peculiar pharmacokinetic proﬁle, linezolid can also
be proposed in IE caused by Gram-positive resistant micro-
Recommendations
Quinupristin/dalfopristin can be considered in selected cases
in the treatment of resistant Gram-positive infectious endocar-
ditis, especiallywhen causedbyvancomycin-resistant E. faecium,
and preferably in combination with other antibiotics (D).Linezolid
No randomized trials addressing the use of linezolid in the
treatment of IE were retrieved. A number of cases describe the use
of linezolid in this condition. Two case series (Falagas et al.23 and
Mun˜oz et al.24) report 33 and nine cases, respectively. In the case
series described by Falagas et al.23 (GRADE score 1), IE was left-
sided in 22 cases and right-sided in 10, while one case involved
both sides. Seven patients had an infection of a prosthetic valve.
The involved microorganisms were MRSA (8/33, 24.2%), VISA or S.
aureus with reduced susceptibility to vancomycin (10/33, 30.3%),
CoNS (5/33, 15.2%), vancomycin-resistant E. faecalis (2/33, 6.1%)
and E. faecium (4/33, 12.1%), and vancomycin-susceptible E. faecalis
(2/33, 6.1%). The reported success rate was 63.6% and the overall
mortality 33%. As inmany reports, data on prolonged follow-up are
lacking in the series by Falagas, so these ﬁgures must be viewed
with caution.Moreover, some of the patients reported to have been
cured, died because of co-morbidities during follow-up. If the
patients who died during follow-up and those classiﬁed as
improved are considered as clinical failures, the overall success
rate is 57.5%. Surprisingly, better results were obtained in patients
with left-sided endocarditis (success rate 60.8%) than in those with
right-sided endocarditis (success rate 50%), and also surprising is
the high success rate (71.4%) reported in patients with prosthetic
valve endocarditis. The impact of surgery on outcome could not be
assessed from these data, however only a minority of patients (8/
33, 24%) were treated with surgery.
Mun˜oz et al.24 (GRADE score 1) reported nine cases of IE treated
with linezolid for refractory disease or intolerance to other
antibiotics, and in three cases as an oral consolidation treatment
for outpatients. All nine patients were cured, with a reasonable
length of follow-up. Seven patients had left-sided IE, and in four of
them a prosthetic valve was involved. The involved agent was
MSSA in four cases and MRSA in two; E. faecalis was isolated (in
association with MRSA) in one case, while the remaining three
cases were caused by S. mutans, C. striatum, and CoNS. Surgery was
performed in four cases.
In single case reports, linezolid has been used with variable
success. In three cases41–43 (GRADE score 1 for each) treatment
with linezolid was associated with clinical failure. All were left-
sided IE. In one case of mitral valve IE caused by MRSA42 (GRADE
score 1), linezolid was reported to be associated with negativity of
blood cultures, though the patient died because of a Candida
sepsis. Clinical success was reported in a further three cases30,37,38
(GRADE score 1 for each); twowere right-sided IE and onewas left-
sided IE; linezolid was used in combination with high dose
daptomycin in one case30 (GRADE score 1).
possible option. Association with other antibiotics must be
considered on an individual basis (D)In conclusion, the use of linezolid in the treatment of IE is not
supported by comparative studies; however in the 50 cases
reported in the medical literature, linezolid appears to be
associated with a reasonable success rate, around 50%. A selection
bias must nonetheless be considered, as successful treatments are
probably more likely to be published than treatment failures. In
some cases37,45 (GRADE score 1 for each) successful treatmentwith
linezolid after failure of other regimens was attributed to the
presence of metastatic embolization in the lung and brain,
respectively, while in another case complicated with cerebral
embolization46 (GRADE score 1), failure of treatmentwith linezolid
was reported. Treatment with linezolid was associated with
thrombocytopenia in about 30% of cases.Quinupristin/dalfopristin
Noclinical trials addressing theuseofquinupristin/dalfopristin in
infectious endocarditis have been reported in the literature, and also
evidence from case reports is scarce. There have been reports of
successful treatment with quinupristin/dalfopristin in cases of
infectious endocarditis caused by MRSA, vancomycin-resistant E.
faecium, and S. epidermidis, either right- or left-sided. In these
successful cases,quinupristin/dalfopristinhasbeenusedeitheralone
or in combination with other antibiotics (vancomycin; vancomy-
cin + levoﬂoxacin; doxycycline + rifampin). Some of these cases also
underwent heart surgery. There have also been reports of failure of
quinupristin/dalfopristin. The cumulative number of case reports is
however very small and does not allow conclusions to be drawn.
Tigecycline
There is insufﬁcient literature regarding the use of tigecycline in
the treatment of infectious endocarditis.
organismsassociatedwithmetastatic septic foci (e.g.,meningitis,
brain abscesses, and splenic and pulmonary emboli) (D).4.8.4. Query 6
In the treatment of sepsis caused by multi-resistant Gram-
positive microorganisms, is therapy with quinupristin/dalfopris-
tin, linezolid, daptomycin, and tigecycline effective?
The literature on sepsis is somehow confusing, owing to the
incorrect use of the terms bloodstream infection, sepsis, and
bacteremia as synonyms. For the purpose of this study, we chose to
limit the search to the MeSH term ‘sepsis’, but to use the term
There is insufﬁcient available evidence on the use of
tigecycline in the treatment of IE.
Recommendations
Therapeutic drugmonitoring of plasma levels of vancomycin
in the management of infective endocarditis is useful and
probably cost-effective (C). Trough levels of at least 15–20 mg/
ml should be obtained. There is a lack of published evidence
regarding the use of TDM for teicoplanin. When using
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The majority of comparative studies on the use of the new
antibiotics in the treatment of sepsis47–51 (GRADE scores 2, 2, 1, 1,
and 3, respectively) have compared linezolid with the glycopep-
tides vancomycin and teicoplanin. Few differences between
linezolid and comparators were noted in these studies, so that it
can be stated that linezolid is at least comparable to glycopeptides
in the treatment of sepsis caused by resistant Gram-positive
microorganisms. Only one study49 (GRADE score 1) showed
linezolid to be superior to teicoplanin,whose dosagewas, however,
at the discretion of the investigator. The quality of the studies is
generally poor except for one study with a double-blind, double-
dummy design. One out of the six studies on linezolid52 (GRADE
score 2) was a comparative study of two different modalities of
administration (continuous vs. intermittent) of the drug. There
were no differences in the two arms. The limited evidence does not
support continuous administration of linezolid in this condition.
In conclusion, the studies seem to show that linezolid activity is
comparable to that of glycopeptides in the treatment of sepsis by
Gram-positive microorganisms.
The only comparative study on quinupristin/dalfopristin53
(GRADE score 2) did not show a difference with the comparator
(standard treatment) in a population of patients with sepsis and
severe underlying conditions. The quinupristin/dalfopristin arm
had bettermicrobiological responses, but the overallmortalitywas
high in both groups.
No data on daptomycin and tigecycline were found.Recommendations
In the treatment of bloodstream infections caused by multi-
resistant Gram-positive microorganisms, linezolid may be used
in selected cases (C). The use of continuous infusion of linezolid
is currently being investigated, but it is not yet supported by the
current evidence (C).
Quinupristin/dalfopristin can be considered in the treatment
of selected cases of bloodstream infections caused by vanco-
mycin-resistant E. faecium (C). There is insufﬁcient evidence to
teicoplanin, a trough concentration of 20 mg/ml should be
obtained (D). Monitoring of plasma levels of other antibiotics is4.9. Diagnostic/laboratory monitoring area
4.9.1. Query 1
In the treatment of infective endocarditis caused by multi-
resistant Gram-positive microorganisms, is monitoring of plasma
levels of vancomycin, gentamicin, and teicoplanin effective in
reducing adverse events and costs, and increasing treatment
efﬁcacy?
The evidence to answer this query is very scarce. Monitoring of
plasma levels of drugs is useful when these are critical to obtain a
therapeutic effect, or when the therapeutic levels of the drugs are
close to the toxic concentrations. In the treatment of infectious
endocarditis, the need tomaintain adequate plasma levels of drugs
also has a theoretical basis, given the difﬁculty of attaining
adequate antibiotic concentrations in the vegetations. Many
studies on pharmacokinetics and/or pharmacodynamics of anti-
biotics have been conducted in this ﬁeld, but the analysis of this
type of evidence is beyond the scope of this work. In clinical
practice, monitoring of plasma levels of the antibiotics used for the
treatment of infective endocarditis is limited to the monitoring of
vancomycin, gentamicin and, less frequently, teicoplanin. Moni-
toring of plasma levels of drugs is costly, so the analysis was
support the use of tigecycline in the treatment of bloodstream
infections.restricted to cost-effectiveness studies. Only two studies were
retrieved, showing thatmonitoring of plasma levels of vancomycin
can be cost-effective, and can be associated with fewer episodes of
renal failure, decreased length of therapy, and possibly reduced
length of stay. None of the studies, however, was conducted on
populations with infective endocarditis.
In the study by Ferna´ndez de Gatta et al.55 (GRADE score 2) the
study population was composed of immunocompromised febrile
patientswith hematologicalmalignancies, assigned to vancomycin
either because of fever resistant to antibiotic treatment (ceftazi-
dime + amikacin) or because of strong suspicion of infection due to
Gram-positive organism. The proportion of patients with infec-
tious endocarditis is unknown. In the study by Welty and Copa56
(GRADE score 1), only two patients (among the 116 studied) had
infective endocarditis.
In conclusion, there is only indirect evidence of the clinical
usefulness of therapeutic drug monitoring of antibiotics in the
management of infective endocarditis, and the evidence is limited
to the monitoring of vancomycin.Acknowledgement
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supported only by animal or PK/PD studies and cannot therefore
be generalized to all clinical situations (D).
Appendix A. Inclusion criteria and search strings for each query
Therapeutic area
Query Inclusion criteria Search string
1. In the treatment of infective
endocarditis caused by
Gram-positive
microorganisms, is
combination therapy with
an aminoglycoside plus
another antibiotic more
effective than monotherapy?
Population: adults with infective endocarditis caused
by a Gram-positive microorganism
Intervention: treatment with an antibiotic
Comparator: treatment with another drug or schedule
Outcome: clinical success; mortality; hospital stay; costs
Description of studies: randomized controlled
trials; other comparative studies (also
retrospective); systematic revisions; meta-analyses
(‘endocarditis’[MeSH Terms] OR ‘endocarditis’[All
Fields]) AND (‘humans’[MeSH Terms] AND (Clinical
Trial[ptyp] OR Meta-Analysis[ptyp] OR Randomized
Controlled Trial[ptyp] OR Clinical Trial, Phase II[ptyp]
OR Clinical Trial, Phase III[ptyp] OR Clinical Trial,
Phase IV[ptyp] OR Comparative Study[ptyp] OR
Controlled Clinical Trial[ptyp] OR Multicenter
Study[ptyp]) AND ‘adult’[MeSH Terms])a
2. In the treatment of infective
endocarditis caused by Gram-
positive microorganisms, is
therapy with an
aminoglycoside in a single
daily dose more effective
than therapy in three
divided doses?
Population: adults with infective endocarditis
caused by a Gram-positive microorganism
Intervention: treatment with an antibiotic
Comparator: treatment with another drug or schedule
Outcome: clinical success; mortality; hospital stay; costs
Description of studies: randomized controlled trials;
other comparative studies (also retrospective);
systematic revisions; meta-analyses
(‘endocarditis’[MeSH Terms] OR ‘endocarditis’[All
Fields]) AND (‘humans’[MeSH Terms] AND (Clinical
Trial[ptyp] OR Meta-Analysis[ptyp] OR Randomized
Controlled Trial[ptyp] OR Clinical Trial, Phase II[ptyp]
OR Clinical Trial, Phase III[ptyp] OR Clinical Trial,
Phase IV[ptyp] OR Comparative Study[ptyp] OR
Controlled Clinical Trial[ptyp] OR Multicenter
Study[ptyp]) AND ‘adult’[MeSH Terms])a
3. In the treatment of infective
endocarditis caused by Gram-
positive microorganisms, is
therapy with teicoplanin as
effective, and associated with
fewer adverse events, than
therapy with vancomycin?
Population: adults with infective endocarditis caused
by a Gram-positive microorganism
Intervention: treatment with an antibiotic
Comparator: treatment with another drug or schedule
Outcome: clinical success; mortality; hospital stay; costs
Description of studies: randomized controlled trials;
other comparative studies (also retrospective);
systematic revisions; meta-analyses
(‘endocarditis’[MeSH Terms] OR ‘endocarditis’[All
Fields]) AND (‘humans’[MeSH Terms] AND (Clinical
Trial[ptyp] OR Meta-Analysis[ptyp] OR Randomized
Controlled Trial[ptyp] OR Clinical Trial, Phase II[ptyp]
OR Clinical Trial, Phase III[ptyp] OR Clinical Trial,
Phase IV[ptyp] OR Comparative Study[ptyp] OR
Controlled Clinical Trial[ptyp] OR Multicenter
Study[ptyp]) AND ‘adult’[MeSH Terms])a
4. In the treatment of infective
endocarditis caused by Gram-
positive microorganisms,
what is the optimal
duration of treatment?
Population: adults with infective endocarditis caused
by a Gram-positive microorganism
Intervention: treatment with an antibiotic
Comparator: treatment with another drug or schedule
Outcome: clinical success; mortality; hospital stay; costs
Description of studies: randomized controlled trials;
other comparative studies (also retrospective);
systematic revisions; meta-analyses
(‘endocarditis’[MeSH Terms] OR ‘endocarditis’[All
Fields]) AND (‘humans’[MeSH Terms] AND
(Clinical Trial[ptyp] OR Meta-Analysis[ptyp] OR
Randomized Controlled Trial[ptyp] OR Clinical
Trial, Phase II[ptyp] OR Clinical Trial, Phase III[ptyp]
OR Clinical Trial, Phase IV[ptyp] OR Comparative
Study[ptyp] OR Controlled Clinical Trial[ptyp] OR
Multicenter Study[ptyp]) AND ‘adult’[MeSH Terms])a
5. In the treatment of infective
endocarditis caused by multi-
resistant Gram-positive
microorganisms, is therapy
with quinupristin/dalfopristin,
linezolid, daptomycin and
tigecycline effective?
Population: adults with infective endocarditis caused
by a Gram-positive microorganism
Intervention: treatment with quinupristin/dalfopristin,
daptomycin, linezolid or tigecycline
Comparator: treatment with other drugs
Outcome: clinical success; mortality; hospital stay; costs
Description of studies: randomized controlled trials;
other comparative studies (also retrospective);
systematic revisions; meta-analyses
(‘linezolid ‘[Substance Name] OR ‘tigecycline
‘[Substance Name] OR ‘Daptomycin’[MeSH]
OR ‘quinupristin-dalfopristin ‘[Substance
Name]) AND ‘endocarditis/drug
therapy’[MeSH] AND (‘humans’[MeSH
Terms] AND (Clinical
Trial[ptyp] OR Meta-Analysis[ptyp] OR
Randomized Controlled Trial[ptyp] OR
Review[ptyp] OR Clinical Trial, Phase
I[ptyp] OR Clinical Trial, Phase II[ptyp] OR Clinical Trial,
Phase III[ptyp] OR Clinical Trial, Phase IV[ptyp]
OR Comparative Study[ptyp] OR Controlled
Clinical Trial[ptyp] OR Multicenter Study[ptyp]))
6. In the treatment of sepsis
caused by multi-resistant
Gram-positive
microorganisms, is therapy
with quinupristin/dalfopristin,
linezolid, daptomycin and
tigecycline effective?
Population: adults with sepsis caused by a Gram-positive
microorganism
Intervention: treatment with quinupristin/dalfopristin,
daptomycin, linezolid or tigecycline
Comparator: treatment with other drugs
Outcome: clinical success; mortality; hospital stay; costs
Description of studies: randomized controlled trials; other
comparative studies (also retrospective); systematic
revisions; meta-analyses
(‘linezolid ‘[Substance Name] OR ‘tigecycline
‘[Substance Name] OR ‘Daptomycin’[MeSH] OR
‘quinupristin-dalfopristin ‘[Substance Name])
AND ‘Sepsis’[MeSH] AND (‘humans’[MeSH Terms]
AND (Clinical Trial[ptyp] OR Meta-Analysis[ptyp]
OR Randomized Controlled Trial[ptyp] OR Review[ptyp]
OR Clinical Trial, Phase I[ptyp] OR Clinical Trial,
Phase II[ptyp] OR Clinical Trial, Phase III[ptyp] OR
Clinical Trial, Phase IV[ptyp] OR Comparative
Study[ptyp] OR Controlled Clinical Trial[ptyp] OR
Multicenter Study[ptyp]))
7. In the treatment of infections
of vascular prostheses caused
by multi-resistant Gram-
positive microorganisms, is
therapy with quinupristin/
dalfopristin, linezolid,
daptomycin and tigecycline
effective?
Population: adults with infection of vascular prostheses
caused by a Gram-positive microorganism
Intervention: treatment with quinupristin/dalfopristin,
daptomycin, linezolid or tigecycline
Comparator: treatment with other drugs
Outcome: clinical success; mortality; hospital stay; costs
Description of studies: randomized controlled trials; other
comparative studies (also retrospective); systematic
revisions; meta-analyses
(‘Prosthesis-Related Infections’[MeSH] AND ‘drug
therapy ‘[Subheading]) AND ‘Blood Vessel
Prosthesis’[MeSH]a
a With a more speciﬁc search strategy no study was retrieved.
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Diagnostic/laboratory monitoring area
Query Inclusion criteria Search string
1. In the treatment of infective
endocarditis caused by multi-
resistant Gram-positive
microorganisms, is monitoring
of plasma levels of vancomycin,
gentamicin and teicoplanin
effective in reducing adverse
events and costs, and in
increasing treatment efﬁcacy?
Population: adults with infective endocarditis caused by a
Gram-positive microorganism
Intervention: treatment with monitoring of plasma levels
of antibiotics
Comparator: treatment without monitoring
Outcome: clinical success; mortality; hospital stay; costs
Description of studies: randomized controlled trials; other
comparative studies (also retrospective); systematic
revisions; meta-analyses
((‘Teicoplanin’[MeSH] OR ‘Vancomycin’[MeSH]) OR
‘Gentamicin’[MeSH]) AND ‘Drug Monitoring’[MeSH]
AND (‘humans’[MeSH Terms] AND (Clinical Trial[ptyp]
OR Meta-Analysis[ptyp] OR Randomized Controlled
Trial[ptyp] OR Clinical Trial, Phase II[ptyp] OR Clinical
Trial, Phase III[ptyp] OR Clinical Trial, Phase IV[ptyp]
OR Comparative Study[ptyp] OR Controlled Clinical
Trial[ptyp] OR Multicenter Study[ptyp]) AND
‘adult’[MeSH Terms])
2. In the treatment of infective
endocarditis caused by multi-
resistant Gram-positive
microorganisms, is the use of
serum bactericidal and synergy
testing (along with traditional
methods such as MIC
determination) effective in
reducing adverse events and
costs, and in increasing
treatment efﬁcacy?
Population: adults with infective endocarditis caused by a
Gram-positive microorganism
Intervention: treatment with use of serum bactericidal
and synergy testing
Comparator: treatment without this testing
Outcome: clinical success; mortality; hospital stay; costs
Description of studies: randomized controlled trials; other
comparative studies (also retrospective); systematic
revisions; meta-analyses
((synergy[All Fields] AND (‘research design’[MeSH
Terms] OR (‘research’[All Fields] AND ‘design’[All Fields])
OR ‘research design’[All Fields] OR ‘testing’[All Fields])) OR
(bactericidal[All Fields] AND (‘serum’[MeSH Terms] OR
‘serum’[All Fields]))) AND (‘endocarditis’[MeSH Terms] OR
‘endocarditis’[All Fields]) AND (‘humans’[MeSH Terms]
AND (Clinical Trial[ptyp] OR Meta-Analysis[ptyp] OR
Randomized Controlled Trial[ptyp] OR Clinical Trial,
Phase II[ptyp] OR Clinical Trial, Phase III[ptyp] OR
Clinical Trial, Phase IV[ptyp] OR Comparative Study[ptyp]
OR Controlled Clinical Trial[ptyp] OR Multicenter
Study[ptyp]) AND ‘adult’[MeSH Terms])
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